Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults
Sponsor: Pfizer
Summary
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-07999415) in healthy adult participants. This study is seeking volunteers aged 18 to 65 years old who do not have any major health issues. Some participants in this study will receive a single dose of PF-07999415 as a shot in the thigh, abdomen, or arm at the study clinic. Afterward, participants will stay in a hospital-like setting for 2 weeks, where they will be monitored for reactions to the study medicine. The study team will compare the experiences of people receiving PF-07999415 to those of the people who do not. This will help the study team decide if PF-07999415 is safe. Participants will take part in this study for 3 to 7 months. During this time, participants will stay at the healthcare facility for 2 weeks and then come back for study visits every 2 weeks until completing the study.
Official title: A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBOCONTROLLED, SINGLE DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF PF-07999415 IN HEALTHY ADULT PARTICIPANTS
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-06-20
Completion Date
2026-08-22
Last Updated
2026-03-20
Healthy Volunteers
Yes
Conditions
Interventions
PF-07999415
Participants will receive single doses of PF-07999415.
Placebo
Participants will receive matching placebo.
Locations (1)
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium